# Nathan Every

> Nathan Every is a Series D investor at Frazier Healthcare Partners backing Health Care. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures)
- Total investments: 11
- Last investment: Jul 2025
- Lead investor: 18%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/nathan-every-4016b410

Nathan Every is a Series D investor at Frazier Healthcare Partners focused on Health Care and Biotechnology. Every is a cardiologist who has been with Frazier Healthcare since 1999, became a partner in 2001 and General Partner in 2005. Every is a member of Frazier's Growth Equity and Biopharma Venture teams. Exited investments include Biostent (acquired by Abbott), Calibra Medical (acquired by LifeSpan), Rigel (NASDAQ), Flowcardia (acquired byC.R. Bard), BARRX, (acquired by Covidien) and Ascension Orthopedics (acquired by Integra Lifesciences). Every currently serves on the boards of Cardiac Dimensions, Correct Care Solutions, Silvergate, PowerVision, Packaging Coordinators and Abode Healthcare.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 45% |
| Biotechnology | 4 | 36% |
| Medical | 3 | 27% |
| Medical Device | 3 | 27% |
| Health Diagnostics | 2 | 18% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 4 | 36% |
| Series B | 3 | 27% |
| Series C | 2 | 18% |
| Funding Round | 1 | 9% |
| Private Equity | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Knipper Health | J. Knipper & Company's mission is to work with theiour clients to create solutions that are strategically designed, faithfully executed, and driven by market insight and data to ensure maximum return on their clients’ investment, and ultimately to improve people’s lives. Their services, ranging from direct marketing and sampling through todata analytics and Web-based applications, are grounded in robust systems and regulatory rigor, as well as years of seeing what works and what doesn’t. |  | Private Equity | Jul 08, 2025 |  |
| PowerVision | PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clearvision at all distances.Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s.PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does.For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again. | $20M | Series D | Jan 29, 2014 |  |
| PowerVision | PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clearvision at all distances.Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s.PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does.For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again. | $24M | Series C | Jul 15, 2011 |  |
| BARRX Medical | BÂRRX Medical, Inc. develops endoscopic treatment solutions for Barrett's esophagus and other chronic gastroenterological diseases. Barrett's is a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. The company's HALOFLEX, HALO360 and HALO90 ablation systemsare designed to provide a uniform and controlled ablation effect, in order to remove diseased tissue and allow re-growth of normal cells.A multi-center randomized, sham-controlled study, published in the New England Journal of Medicine in 2009, studied HALO radiofrequency ablation applied in the highest risk Barrett's population (those having dysplasia). The ablation group had a high rate of complete eradication of dysplasia and intestinal metaplasia and a significantly decreased rate of disease progression and cancer development, as compared to the control group. In another study (AIM-II) published in Gastrointestinal Endoscopy, 98.4% of treated patients were Barrett's-free after two and a half years of follow-up.The HALO systems are cleared by the FDA for use in the United States and each have CE Mark for use in Europe. More than 58,000 procedures have been performed in over 400 hospitals around the world. Based in Sunnyvale, Calif., BÂRRX Medical, Inc. was founded in 2000 and is privately-held. | $15M | Series D | Jul 14, 2010 |  |
| Zeltiq Aesthetics | Zeltiq (pronounced Zel ′teek) Aesthetics, founded in 2005, is a science-based medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat tissue. The Zeltiq approach utilizes a patented method called Cryolipolysis™ (the use of precisely controlled cooling to remove fat) that is designed totarget only fat cells and not harm the skin or other tissue.The Zeltiq device is cleared by the FDA in the Unites States for various applications related to skin cooling during dermatologic treatments. | $25M | Series D | Jun 03, 2010 |  |
| Calibra Medical | Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California. | $1.4M |  | Nov 24, 2009 |  |
| Calibra Medical | Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California. | $35M | Series B | Aug 01, 2008 |  |
| PowerVision | PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clearvision at all distances.Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s.PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does.For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again. | $20M | Series B | Dec 31, 2007 |  |
| Cardiac Dimensions | Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $35.5M | Series D | Dec 30, 2007 |  |
| Cardiac Dimensions | Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $15M | Series C | Mar 17, 2004 |  |

10 of 11 investments shown.

## Co-investors
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 3 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 2 deals together
- [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners) — VC Fund, 2 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 2 deals together
- [Medtronic](https://shizune.co/investors/profile/medtronic) — VC Fund, 2 deals together
- [Skyline Ventures](https://shizune.co/investors/profile/skyline-ventures) — VC Fund, 2 deals together

## About Frazier Healthcare Partners

VC Fund · Seattle, United States

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations.Frazier’sexperienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.

5 contacts available at Frazier Healthcare Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Nathan Every | General Partner | https://shizune.co/investors/profile/nathan-every |
| Patrick Heron | General Partner | https://shizune.co/investors/profile/patrick-heron |
| Tadataka Yamada | Senior Entrepreneur in Residence | https://shizune.co/investors/profile/tadataka-yamada |
| Alan D. Frazier | Managinig Partner, Founder & Chairman | https://shizune.co/investors/profile/alan-d-frazier |
| Bob Baltera | Entrepreneurs In Residence | https://shizune.co/investors/profile/bob-baltera |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Nathan Every invest in?

Nathan Every invests primarily in Health Care, Biotechnology and Medical startups, most often at Series D and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Nathan Every last invest?

The most recent investment recorded for Nathan Every closed in Jul 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co